Andrew Larry Frelinger III on Activation of Platelets in Flow Cytometry
Andrew Larry Frelinger III, Director Emeritus, Center for Platelet Research Studies Corresponding Faculty, Dept. of Pediatrics at Harvard Medical School, shared on LinkedIn:
”I am very pleased to share this publication which came about through a great collaboration with the Steve Watson lab.
The paper explores activation of GPVI, CLEC-2 and PEAR1 using multivalent nanobodies.
Special thanks to Rachel Lamerton for spearheading the work, Elenya Martin for preparing the nanobodies, and Jax Perry for the performing and analyzing the spectral cytometry assays.
These fantastic tools may aid in the development of assays to assess platelet function disorders.
Enjoy!”
Read the full article in RPTH.
Article: A minimum valency of 4 is required for robust activation of platelets in flow cytometry by multivalent nanobodies to Glycoprotein VI, C-type lectin-like receptor 2 and Platelet Endothelial Aggregation Receptor 1
Authors: Rachel E. Lamerton, Eleyna M. Martin, Jacqueline Perry, Adam F. Cunningham, Steve P. Watson, Andrew Larry Frelinger III
Stay updated on all scientific advances with Hemostasis Today.
-
Feb 2, 2026, 17:54Danny Gaskin: Nominations are Open for the BBTS Transfusion Practitioner Special Interest Group Award 2026
-
Feb 2, 2026, 17:44Important Webinar on Care for Patients with iTTP – ISTH
-
Feb 2, 2026, 17:21Tagreed Alkaltham: Some Risks Don’t Look Like Risks in Healthcare
-
Feb 2, 2026, 17:16Sifat Jubaira: Effect of Prolonged Tourniquet Application
-
Feb 2, 2026, 17:14Vivek Mahto: Understanding Deep Vein Thrombosis – Causes, Symptoms, and Prevention
-
Feb 2, 2026, 17:08Tareq Abadl: Heparin vs Warfarin
-
Feb 2, 2026, 17:07Mary Cushman: New Research on Aspirin Use in Pregnancy and Stroke Risk in Offspring
-
Feb 2, 2026, 16:52Aravind Palraj: Young Stroke is Never Just Stroke
-
Feb 2, 2026, 16:48Seyed Mohsen Jahromi Moghadam: Antithrombotic Therapy After Transcatheter Structural Heart Interventions